This article is more than 5 years old. Information may no longer be current.
Medtronic receives FDA approval for quadripolar lead, two CRT devices
Medtronic today announced that the FDA has approved the Attain Performa Model 4298 quadripolar lead and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators.
The lead and both devices will be available to physicians in September, according to a company press release.
The Viva Quad XT utilizes VectorExpress technology, which aids in selecting optimal pacing configurations for each patient by providing clinically useful information and reducing lead programming time by 2 minutes. The Quad XT device also incorporates AdaptivCRT, an algorithm that preserves normal heart rhythms and automatically adjusts to individual patients, according to the release. The Attain Performa Model 4298 left-heart lead has a canted shape, and features 16 pacing configurations and a shorter space between the center electrodes. It was designed to reduce the incidence of phrenic nerve stimulation, according to the release.
“Compared to conventional leads, the additional pacing configurations offered by this system provide implanting physicians more options to optimize CRT delivery, which results in better patient care,” George H. Crossley, MD, FACC, FHRS, associate professor at Vanderbilt Heart and Vascular Institute in Nashville, Tenn., said in the release.